Differentiation between temporary and real non-clearability of biotinylated IgG antibody by avidin in mice by Dou, Shuping et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Radiology Publications and Presentations Radiology 
2014-07-24 
Differentiation between temporary and real non-clearability of 
biotinylated IgG antibody by avidin in mice 
Shuping Dou 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/radiology_pubs 
 Part of the Medical Pharmacology Commons, Medicinal and Pharmaceutical Chemistry Commons, 
Medicinal Chemistry and Pharmaceutics Commons, Radiology Commons, and the Therapeutics 
Commons 
Repository Citation 
Dou S, Virostko J, Rusckowski M, Greiner DL, Powers AC, Liu G. (2014). Differentiation between temporary 
and real non-clearability of biotinylated IgG antibody by avidin in mice. Radiology Publications and 
Presentations. https://doi.org/10.3389/fphar.2014.00172. Retrieved from 
https://escholarship.umassmed.edu/radiology_pubs/38 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Radiology Publications 
and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
ORIGINAL RESEARCH ARTICLE
published: 24 July 2014
doi: 10.3389/fphar.2014.00172
Differentiation between temporary and real non-clearability
of biotinylated IgG antibody by avidin in mice
Shuping Dou1, John Virostko2, Mary Rusckowski1, Dale L. Greiner3, Alvin C. Powers4,5,6 and
Guozheng Liu1*
1 Department of Radiology, University of Massachusetts Medical School, Worcester, MA, USA
2 Vanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA
3 Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
4 Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University, Nashville, TN, USA
5 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
6 Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
Edited by:
Chiranjib Chakraborty, Galgotias
University, India
Reviewed by:
Rahman M. Mizanur, US Army
Medical Research Institute of
Infectious Diseases, USA
Miaozong Wu, Marshall University,
USA
*Correspondence:
Guozheng Liu, Department of
Radiology, University of
Massachusetts Medical School,
55 Lake Avenue North, Worcester,
MA 01655-0243, USA
e-mail: guozheng.liu@
umassmed.edu
Although an increasing number of antibody conjugates are being used in the clinic, there
remain many unmet needs in antibody targeting. Normal tissue background is one of the
key issues that limits the therapeutic efficacy and the detection sensitivity. Background
reduction coupled with dose increase may provide the required target accumulation of the
label or toxin at an acceptable normal tissue background. However, the knowledge about
the in vivo interaction between antibody and a clearing agent is currently inadequate for
designing a rational clearance regimen or system. The current investigation focuses on the
clearability of antibody for background reduction, an important topic to antibody targeting
in general. The investigation employs pretargeting as a research tool and avidin as a model
clearing agent. By comparing the effects of natural clearance at a longer post-injection
time and avidin clearance, we demonstrated that avidin clearance is much more effective.
By directly attaching avidin to a biotinylated antibody prior to injection, we found that
the biotinylated antibody in blood, once bound to the clearing agent, can be removed
from the circulation immediately and completely, while the real non-clearable antibody
without biotin stays. The study of multiple avidin injections confirmed that the presence
of clearable biotinylated antibodies after an avidin injection is due to their temporary
inaccessibility and subsequent return from tissue compartments. The collective clearance
efficiency of 91% by three avidin injections indicates a continuous IV infusion would be
recommended to remove all of the biotinylated IgG molecules. In conclusion, the use of
antibody pretargeting as a tool in this study has improved understanding of the incomplete
clearance by avidin and can aid in overcoming this obstacle.
Keywords: pretargeting, antibody, clearing agent, avidin, in vivo accessibility, immunotargeting
INTRODUCTION
For targeted immunotherapy and immunodiagnosis, the clear-
ance of normal tissue background is an important measure
complementary to the enhancement of target accumulation.
Although targeted immunochemotherapy of hematological can-
cer has achieved great success (Senter and Sievers, 2012; Deng
et al., 2013), the relative poorer accessibility of antibody to solid
tumors remains a challenge. Reducing the normal tissue back-
ground may allow for increasing the dose of the “warhead” or the
target toxicity and therefore may improve solid tumor treatment.
The background reduction is also critical for imaging the islets
of Langerhans (Liu et al., 2011, 2012). Because islets constitute
only 1–2% of the pancreas mass and the current nuclear imaging
technologies cannot differentiate islets from non-islet pancreatic
tissues, reduction of the non-specific binding in the exocrine tis-
sues is crucial to assure the pancreas signal reflects the beta cell
accumulation.
Currently, there are two clearing mechanisms in the liter-
ature used for reducing the normal tissue background. One
mechanism using a secondary-antibody takes advantage of the
large size of the aggregate formed with the pretargeting anti-
body. The aggregate can be removed from the circulation by
reticuloendothelial (RE) cells (Goodwin et al., 1994, 1988).
The other mechanism employs a clearing agent bearing galac-
tosyl groups. Such clearing agents can be avidin (Yao et al.,
1995; Mirallie et al., 2005; Liu et al., 2010), galactosylated anti-
antibodies against the pretargeting antibody (Sharkey et al.,
1997), or galactosylated and biotinylated HSA (Axworthy et al.,
2000). The complex formed between the antibody and clearing
agent can be removed by an asialoglycoprotein receptor spe-
cific for the galactosyl groups (Ashwell and Morell, 1974; Ong
et al., 1991). Both mechanisms traffic the circulating pretarget-
ing molecules into liver. Most studies in the literature focus on
the development of technologies that include a clearance step
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(Ashwell and Morell, 1974; Goodwin et al., 1988, 1994; Ong et al.,
1991; Yao et al., 1995; Karacay et al., 1997; Sharkey et al., 1997;
Axworthy et al., 2000; Wang et al., 2001; Mirallie et al., 2005; Liu
et al., 2010). However, few efforts have been made to understand
the in vivo interaction between the antibody and clearing agent
(Kobayashi et al., 1995; Yao et al., 1995; Sharkey et al., 1997).
The clearance concept has been used for many years, but the
current knowledge remains inadequate for readily designing a
targeting system with a clearance step to achieve low blood back-
ground. The current investigation focuses on the clearability of
biotinylated antibody using avidin as a clearing agent. It is known
that avidin does not clear biotinylated antibody completely, but
there is no quantitative study as to the exact cause. However, this
topic is very important not only for developing a pretargeting
technology with clearance, but also for any antibody-based drug
for which the background is a concern.
In the current investigation, we employed a model pretarget-
ing system to investigate the in vivo chemistry between avidin
and biotinylated IgG antibody. The aim of this study is not to
develop an improved pretargeting protocol but to understand the
clearability of biotinylated antibody by avidin. As such, the pretar-
geting system is used as a research tool for understanding rather
than solely for improved pretargeting technology. In this pretar-
geting system, the antibody CC49 is conjugated concomitantly
with a biotin and a morpholino phosphorodiamidate oligomer
(MORF). The biotin functions to bind to the clearing agent
of avidin, whereas the MORF is for radiolabeling both in vivo
and in vitro. In contrast to most clearance systems, the current
design has avoided the binding competition between the clear-
ing agent and the effector. In this investigation, normal mice are
used to focus on the determinants of antibody clearance. Tumor
accumulation will not be compromised by antibody clearance as
previously concluded (Liu et al., 2010).
MATERIALS AND METHODS
The MORF and cMORF (complementary MORF) were custom-
synthesized by Gene Tools, LLC (Philomath, OR). Their base
sequences and amine derivatization were the same as previously
reported (Liu et al., 2010). The EZ™ Biotin Quantitation Kit
and avidin were from Pierce (Thermo Fisher Scientific, Rockford,
IL). The model antiTAG-72 IgG antibody CC49 was prepared by
Strategic Biosolutions (Ramona, CA) from its murine hybridoma
cell line (a gift from Dr. Jeff Schlom, Center for Cancer Research,
NCI, NIH). The biotin-CC49-MORF was synthesized following
the reactions illustrated below (Scheme 1) and characterized as
previously described (Liu et al., 2010).
Scheme 1 | The reactions of antibody conjugation with both biotin and
MORF.
The 99mTc-cMORF was prepared following a documented
procedure (Liu et al., 2006). The 99Mo-99mTc generator was from
Perkin Elmer Life Science Inc. (Boston, MA). All other chemicals
were reagent grade and used without purification.
The concentrations of MORF and cMORF were measured by
UV spectrophotometry using the molar absorbance values pro-
vided by the vendor. Size exclusion (SE) HPLC was used for
the analyses of the MORF, cMORF and antibody. The HPLC
system was equipped with a superpose-12 10/30 GL column
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden; optimal sep-
aration range: 1 × 103 to 3 × 105 Da), a UV in-line detector,
and a radioactivity in-line detector. A 0.10M pH 7.2 phosphate
buffer was used as the eluant at a flow rate of 0.60mL/min.
Radioactivity recovery was routinely measured and was always
greater than 90%.
We designed three animal studies in the current investigation.
The animal use was approved by the IACUC of the University
of Massachusetts Medical School. We first examined the natu-
ral background-reducing effect of time (prolonging pretargeting
interval) and the use of avidin, to show the strength of clearing
agent and to confirm the pharmacokinetic homogeneity of the
antibody molecules after modification. We then studied the clear-
ability of the biotin-CC49-MORF. The antibody was radiolabeled
and bound to avidin prior to injection into mice, to mimic the
avidin binding of antibody in blood. Based on the results from
the first two studies, we designed a multiple avidin injection study
to confirm that the biotinylated antibody that survived an avidin
clearance was still clearable.
CLEARANCE EFFICIENCY BY AVIDIN WITH VARYING PRETARGETING
INTERVAL
Because a longer wait (pretargeting interval prolongation) also
reduces the non-specific background of antibody, we examined
the effect of pretargeting interval prolongation along with avidin
clearance. The statistical significance for the blood level changes
by pretargeting interval prolongation and avidin clearance was
analyzed by Two-Way analysis of variance (ANOVA) at the sig-
nificant level of 0.05. A new quantity for the effect of avidin
(clearance efficiency) is defined as the %ID/g reduction by avidin
of blood radioactivity as compared to the %ID/g without avidin
(100%—the blood level ratio with/without avidin injection). It
can be calculated from the measured blood activity levels. The
standard deviation of the clearance efficiency can be estimated by
the uncertainty propagation formula:
SD =
√√√√SD2without
(
1
Bloodwith
)2
+ SD2with
(
Bloodwithout
Blood2with
)2
.
To label the antibody in vivo, the cMORF was injected in a
many-fold molar excess as compared to the MORF on the anti-
body. The blood level of the cMORF was therefore proportional
to that of the antibody and was a measure of the antibody
blood level, but it is lower in value than the antibody level
because only a small portion of the cMORF was consumed
and the rest of the cMORFs were excreted rapidly. The rela-
tionship is: %ID/gantibody = %ID/gcMORF/(molar dose ratio of
cMORF/antibody × MORF number per antibody).
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Scheme 2 | The study design examining the clearance effect of longer
wait and avidin injection.
As shown in Scheme 2, in a study set of 3 groups of mice
(N = 4), each of the 12 mice received via tail vein 30µg of biotin-
CC49-MORF (0.67 MORFs and 3.41 biotins per antibody); 1,
2, and 3 days later, an avidin dose of 34µg was administrated
intravenously to the 3 groups of 4 mice, followed 3 h later by the
injection of 1.2µg (80 µCi) of 99mTc-cMORF. The mice were
euthanized for biodistribution at 3 h subsequent to the radioac-
tivity injection. In a control study set, an otherwise identical
procedure was applied except for the removal of the avidin injec-
tion. The 1.2µg of cMORF was an optimized mass dose that was
sufficient to saturate the MORF-antibody and the 34µg of avidin
was previously determined to be more than sufficient to satu-
rate the biotin-modifiedMORF-antibodies in the circulation (Liu
et al., 2010). The decrease of blood radioactivity level of 99mTc-
cMORF was used as the measure of background improvement as
it was proportional to the decrease of the MORF-antibody level.
AVIDIN CLEARABILITY OF THE BIOTIN-ANTIBODY-MORF
As will be shown, although avidin clearance was much more
effective as compared to the prolonged pretargeting interval, the
clearance effect was still considerably low (50–60%). Thus, we
sought to determine whether a biotinylated antibody could be
cleared completely once bound to avidin in blood. We designed a
study to inject biotinylated antibody both radiolabeled and bound
to avidin prior to the IV injection, to mimic the antibody in
blood immediately after binding to avidin. Thus, a biotin-CC49-
MORF antibody (0.63 MORFs and 1.68 biotins per antibody)
was radiolabeled by mixing with 99mTc-cMORF (at a molar ratio
of MORF/cMORF = 3/1). The mixture was purified over a G-
100 size-exclusion column. The radiolabeled biotin-CC49-MORF
was then allowed to combine with excess avidin (molar ratios of
avidin/biotin = 5). The pharmacokinetics of the both radiolabeled
and avidin-bound antibody was then measured. Mice in 4 groups
(N = 4, each group) each received an IV injection of the mixture
containing 12.5µg (9µCi) of 99mTc-labeled biotin-CC49-MORF
and 45µg of avidin. At 2min, 30min, 1.5 h, and 2.5 h, the mice
were euthanized for measuring the biodistribution. In a control
set also consisting of 4 groups (N = 4, each group), an identi-
cal procedure was performed except avidin was not added to the
injectate.
MULTIPLE INJECTIONS OF AVIDIN
As will be shown, the clearance efficiency in the first study was
less than the clearable portion measured in the second study.
We thus sought to determine whether the non-cleared portion is
Scheme 3 | The study design for the pretargeting regimens with
multiple injections of avidin.
temporary non-clearable due to the sequestration of the antibody
in the extravascular space. As shown in Scheme 3, each mouse of
4 groups (N = 4) was injected with 30µg of biotin-CC49-MORF
(0.63 MORFs and 1.68 biotins per antibody). One day after anti-
body injection, mice in groups 2, 3, and 4 were injected with 34µg
of avidin. Two days later, the mice in groups 3 and 4 received
another avidin injection. Three days later, mice in group 4 were
given the third avidin injection. At 3 h following the last avidin
injection of group 4, all mice in groups 1–4 received the same
dose of radiolabeled cMORF (1.1µg, 40µCi) and all mice were
euthanized for biodistribution at 3 h after the cMORF injection.
The clearance effect for each avidin injection was estimated by
comparing the group with that avidin injection as the last avidin
injection to another group without it (group 1 vs. 2 for the first
avidin injection, group 2 vs. 3 for the second, and group 3 vs. 4
for the third).
RESULTS
CLEARANCE EFFICIENCY BY AVIDIN WITH VARYING PRETARGETING
INTERVAL
Both prolonging the pretargeting interval and the use of avidin
reduced the antibody levels in blood as shown in Figure 1 and
normal tissues (not presented), but the use of avidin is more
effective. Two-Way ANOVA indicates that the cMORF blood level
is significantly decreased both by pretargeting interval prolonga-
tion (p = 0.007) and avidin administration (p < 0.00005). With
regard to avidin administration, the result of ANOVA is in agree-
ment with the visual judgment based on the large difference
relative to the SD at each interval. The clearance efficiency using
avidin as a clearing agent is calculated to be 55–58%, with >40%
antibody remaining in the circulation. As will be shown, this
incomplete clearance is neither due to ineffective binding of
avidin nor to the dissociation of the avidin/biotin complex but
mainly results from the rapid clearance of avidin from blood to
liver.
The cleared and the remaining labeled molecules in the cir-
culation seem to share the same pharmacokinetics. The vary-
ing pretargeting interval did not change the clearance efficiency
(Figure 1). No significant difference is evident among the clear-
ance efficiencies at the 1–3 day pretargeting intervals.
AVIDIN CLEARABILITY OF THE BIOTIN-ANTIBODY-MORF
As shown in Figure 2A, the blood concentration of the radiola-
beled biotin-CC49-MORF not treated with avidin is much higher
than that for the avidin-treated. The percentages cleared from
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circulation (1-the ratio of blood levels with/without avidin) are
65± 3%, 84± 1%, 89± 1%, and 88± 1% for 2, 30min, 1.5, and
2 h, respectively. At 0.5 h, the clearance of the avidin-treated anti-
body is almost complete, although additional slight improvement
is observed until 1.5 h. Thus, about 88% of the avidin-treated
biotin-CC49-MORF is clearable. The approximate 12% of avidin
that is non-clearable (that cannot be cleared by avidin) is likely
due to the lack of a biotin group.
The high liver accumulation in Figure 2B confirms the previ-
ous report that avidin clears the antibody into this organ (Ashwell
FIGURE 1 | Clearance efficiency at different pretargeting intervals in a
pretargeting procedure using biotin-CC49-MORF, avidin, and
99mTc-cMORF. The cMORF level is proportional to and used as a measure
of the antibody level. The clearance efficiency is defined as the ratio of
blood level with/without avidin.
and Morell, 1974; Ong et al., 1991). Subsequent clearance out of
this organ is slow, as shown in Figure 2C by the almost identical
whole body retention. The ∼30% loss of the radioactivity in the
whole body is likely due to the lower affinity of some sequence
impurities and therefore the dissociation of the MORF/cMORF
complex. Figure 2D demonstrates higher kidney accumulations
after 30min for the non-avidin-treated antibody as compared to
the avidin-treated, likely due to the higher blood concentrations
of the antibody shown in Figure 2A.
MULTIPLE INJECTIONS OF AVIDIN
As shown in Figure 3, additional injections of avidin subse-
quent to the first further reduce the blood antibody concen-
tration. This indicates that the majority of antibody molecules
that survived the first avidin injection are clearable. The col-
lective clearance efficiency following 3 avidin injections is 80 ±
2% (0.61/3.10∗100%). The separate clearance efficiency follow-
ing each injection is 43 ± 12% (1 − 1.78/3.10), 44 ± 11% (1 −
0.99/1.78), and 38 ± 7% (1 − 0.61/0.99), respectively. The real
clearance efficiency may actually be higher because of the non-
clearable portion. A calculation based on a constant clearance
efficiency of 51% (higher than 38–44%), and the non-clearable
portion of 12% provides the blood concentrations of 3.10, 1.71,
1.03, 0.69%ID/g. These numbers are in a good agreement to
the measured 3.10 ± 0.24, 1.78 ± 0.33, 0.99 ± 0.07, 0.61 ±
0.05%ID/g.
DISCUSSION
In the current investigation, we have demonstrated that
biotinylated antibody can be cleared from the circulation
completely and rapidly if bound to avidin. To the best of our
knowledge, until this investigation it remained a hypothesis,
FIGURE 2 | Pharmacokinetics of both avidin-bound and radiolabeled
biotin-CC49-MORF vs. radiolabeled biotin-CC49-MORF (no avidin).
Shown are pharmacokinetics for (A) Blood, (B) Liver, (C)
whole body retention, and (D) kidney. It mimics how a
biotinylated antibody molecule behaves once bound to avidin in
blood.
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FIGURE 3 | The blood radioactivity levels after the injection of the
biotin-Ab-MORF, different numbers of injections of avidin, and the
injection of the radiolabeled cMORF. The time of euthanization was at 4
days after initial injection of the pretargeting antibody and 3 h after injection
of radiolabeled cMORF (see Materials and Methods).
although the incomplete clearance of antibody by avidin was
known. Yao et al. hypothesized that one of the possible reasons
underlying the incomplete clearance might be a too low biotiny-
lation of the antibody (Yao et al., 1995), because avidin would
not bind an antibody without biotin. In the current investiga-
tion, this possibility was confirmed to be limited to only∼12% for
the MORF-Ab carrying an average of 1.68 biotins per molecule.
Another possible explanation Yao et al. proposed was the inac-
cessibility of the antibody that diffused into the interstitial fluid
(extravascular space). As some clearing agents reached a clearance
effect of >90% (Sharkey et al., 1997; Axworthy et al., 2000), an
auxiliary explanation may be the rapid clearance of avidin rela-
tive to the diffusion into the extravascular space (Mirallie et al.,
2005). It has been reported that most labeled avidin is eliminated
from blood within 2min in rabbits (Rosebrough, 1993). When
the avidin is essentially cleared from circulation, the extravascular
antibodies would return. A rebound of the radiolabeled anti-
body concentration in the blood has been previously observed
(Kobayashi et al., 1995).
The hypothesis that temporary inaccessibility of the anti-
body in the extravascular space, coupled with the rapid clearance
of avidin from the circulation, also explains the avidin dose-
clearance curves (Rosebrough, 1993; Liu et al., 2010). An initial
narrow dose range with efficient improvement in antibody clear-
ance may correspond to the range of saturating the biotinylated
antibody within the blood pool. The subsequent less effective
larger range may reflect the difficulty for the avidin to diffuse
across the capillary wall into the extravascular space due to its
rapid clearance from the blood.
We have employed a pretargeting system to measure the con-
centration of the antibody in the current investigation as well
as previous studies (Liu et al., 2010). The conventional direct-
labeling approach (to compare labeled antibody level in normal
tissues with and without an injection of clearing agent) would
underestimate the clearance efficiency, because radiolabels, par-
ticularly radiometals, may have dissociated from antibody and
localized within the cells. In this study, we have defined the
clearance efficiency. It can also be calculated based on the mea-
surement by pretargeting.
The immediate utility of the findings in this investigation is
that it paves the way for using avidin as the clearing agent to
develop an improved pretargeting technology. The tri-functional
antibody allows for independent binding to the target, to the
clearing agent, and to the labeled effector. In some other pretar-
geting technologies with galactosylated clearing agent, the effec-
tor and the clearing agent compete for the same binding site.
Although the clearance efficiency by a single injection of avidin is
lower than that provided by a single injection of secondary anti-
body (50–60% vs. >90%), it would not affect the endogenous
IgG antibodies in animal and human (Sinitsyn et al., 1989). As
the lower clearance efficiency (50–60%) stems from the too rapid
clearance of avidin, a continuous infusion within 1 or 2 h would
achieve a clearance effect suitable for clinical applications.
More importantly, the topic of antibody-trafficking among
different compartments and its clearance from circulation are of
interest for immunotherapy or targeted chemotherapy ingeneral.
The clearance approach may apply similarly to the antibody-drug
conjugates for tumor targeting. Clearance of the circulating
antibody would greatly reduce the toxicity to normal tissues and
therefore may permit higher dose for increased toxicity to the
tumor.
CONCLUSION
Understanding the in vivo interaction between antibodies and
their clearing agent should be useful for antibody-based drug dis-
covery. We demonstrated the rapid clearance from blood of every
avidin-bound antibody molecule, differentiated the temporary
non-clearable and the real non-clearable antibody molecules, and
validated the previous hypotheses in the literature. We also quan-
titated the clearance processes by defining clearance efficiency and
using pretargeting as a research tool. Based on the multiple injec-
tion study, we suggest a continuous administration (infusion) of
the clearing agent as a solution for the temporary non-clearable
antibodies.
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